CLX has a Zacks Rank #3 (Hold) with less attractive valuation metrics including a higher forward P/E ratio of 14.87, higher PEG ratio of 2.70, and notably higher P/B ratio of 40.72. It received a Value grade of C, suggesting it is less attractive for value investors compared to ADRNY.
Despite beating earnings and sales estimates, Clorox faces significant headwinds including 42% YoY EPS decline, 520 bps gross margin contraction from higher costs, 13% organic sales decline, and 21.06% downward estimate revisions. The stock has underperformed the S&P 500 by 9.3% since earnings, and received a Zacks Rank #4 (Sell) rating with expectations for below-average returns.
CLX receives a Zacks Rank #4 (Sell) rating with a Value grade of C. It has less attractive valuation metrics with a forward P/E of 16.67, PEG ratio of 3.02, and notably high P/B ratio of 46.88, suggesting weaker earnings outlook and overvaluation.
Clorox demonstrates improving fundamentals with the Purell acquisition expanding its health and hygiene segment, completion of ERP overhaul improving operational efficiency, strong projected free cash flow (11-13% of net sales), and 49 consecutive years of dividend increases. The stock trades at an attractive valuation of 16.8x forward earnings with a 5.1% yield, making it appealing for income investors despite near-term consumer spending headwinds.
Despite flat revenue ($7.1B), net income improved significantly ($810M vs $280M), indicating margin recovery post-cyberattack. Trading at P/S ratio of 1.6x well below 10-year average of 2.9x suggests undervaluation. Strong brand positioning with 80% of sales from No. 1 or No. 2 market share products. Author recommends as the safer choice for 2026.
While offering an attractive 5.1% dividend yield and improving FCF trajectory ($761M in 2025 vs. $483M in 2024), the company has concerning high debt-to-equity ratio of 9.0x and significantly lower absolute free cash flow, raising questions about long-term dividend sustainability. Not recommended over P&G despite higher yield.
Mixed outlook: Stock at 11-year low with declining sales guidance and history of missing targets (negative), but attractive 5.7% yield, low valuation at 13.7x earnings, and strategic GOJO acquisition focusing on core cleaning strength (positive). Suitable for patient value investors but requires management to prove execution capability.
Despite achieving Dividend King status, Clorox faces significant red flags including declining sales, margin compression, deteriorating balance sheet with skyrocketing debt levels, and unsustainable dividend payments relative to free cash flow generation. The company's long-term growth depends on brand resilience and pricing power, which remain uncertain.
The article recommends Clorox as a relatively safe, undervalued dividend stock suitable for investors concerned about market volatility and recession risks. Dividend stocks like Clorox typically perform better during economic slowdowns, making it an attractive defensive investment option.
The declaration of a quarterly dividend of $1.24 per share demonstrates the company's financial health and commitment to returning value to shareholders. The emphasis on a long history of regular dividend payments and annual increases signals confidence in the company's earnings stability and growth prospects.
Articles that tag CLX but are mainly about other companies.
Clorox is implementing a streamlined operating model to reduce costs and improve efficiency while expanding in health and hygiene categories. The company's portfolio optimization, innovation investments, and sourcing flexibility support margin management amid cost inflation.
Ranked No. 1 in its industry for trustworthiness, demonstrating strong trust across customer, employee, and investor bases
Stock has recovered from cyberattack and IT upgrade challenges, trading at reasonable 22x earnings with 4.7% dividend yield, strong free cash flow coverage, and expected sales rebound in current fiscal year.
Mentioned as a peer with operating margins under 20%, suggesting weaker margins than Colgate-Palmolive.
48 consecutive years of dividend increases with Dividend King status expected in 2027, recent strategic acquisition of Gojo/Purell brand to expand growth, historically high 5.1% dividend yield, and P/E of 15x well below 5-year average of 37x despite current market pessimism.
Recent $2.25B acquisition of Purell (a category-defining brand) provides significant long-term growth engine. Despite near-term integration costs and earnings guidance cuts, the 5% dividend yield and Morningstar valuation of $134 vs. current $95 price offer attractive long-term value for patient investors.
Despite near-term headwinds (CEO departure, inflation, past hacks), the company has revamped its portfolio and acquired Gojo (leading hand sanitizer brand), providing growth catalyst and expansion into B2B market with attractive 5% yield.
48-year dividend growth streak nearing Dividend King status, trusted consumer brands with consistent demand, 5.2% dividend yield, recent Gojo acquisition expected to boost earnings despite recent challenges.
Despite near-term pain from ERP system transition, the company has 48 years of consecutive dividend growth with no cuts. Recent $2.25 billion acquisition of Gojo Industries (Purell) adds institutional sales channel. Stock down 37% from highs, yielding 5.5%, creating attractive entry point for patient long-term investors.
Referenced as a competitor with substantially lower advertising budget ($800M), used primarily to illustrate P&G's superior scale and marketing capabilities rather than to make a specific judgment about Clorox.
On track for Dividend King status with 48 consecutive years of increases, but facing significant headwinds including pandemic-era missteps, 2023 cyberattack, weak consumer spending, and intense competition. Stock near 11-year low with attractive 5.38% yield and 15.5 P/E ratio. Turnaround potential exists through efficiency improvements and new acquisitions (Gojo/Purell), but execution risk is high. Dividend sustainability depends on improved fundamentals.
Despite recent challenges (cyberattack, margin pressures), the company has decades-long dividend increase streak it will likely maintain, attractive P/E ratio of 14 (well below market average), and strong brand portfolio position it for recovery.
Modest 9% YTD decline demonstrates resilience, 5.4% dividend yield, and significant 20.8% analyst target upside to $107.41. Strong portfolio of essential consumer products and innovation pipeline support defensive positioning.
Everyday necessities with strong gross margins and active investment in innovation and marketing. Discounted valuation with resilient product categories that perform well during market uncertainty.
Trading at 55% discount from all-time high, strong dividend yield (4.7%) with decades of annual increases, low P/E ratio (17), and analyst expectations for sales rebound in fiscal 2027 despite current challenges
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
